Symptom control, functioning and satisfaction among Swiss patients treated with risperidone long-acting injectable

International Journal of Psychiatry in Clinical Practice

Volumn 10, Issue 3, 2006, Pages 174-181

  Nick, Beat ^a   Vauth, Roland ^b   Braendle, Daniel ^c   Riecher Rössler, Anita ^b  

^a Psychiatric Services Canton Solothurn   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c Cilag AG   (Switzerland)

Author keywords

Functioning; Long acting risperidone; Patient satisfaction; Schizophrenia; Tolerability

Indexed keywords

BENZODIAZEPINE; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; RISPERIDONE;

ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MONOTHERAPY; NAUSEA; PARANOID SCHIZOPHRENIA; PARKINSONISM; PATIENT SATISFACTION; PRIORITY JOURNAL; SCORING SYSTEM; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SWITZERLAND; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 33748462663     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651500600633477     Document Type: Article

References (46)

1. Mueser KT, McGurk SR. Schizophrenia. Lancet 2004;363: 2063-72.
2. Kane JM, Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998;8:55-66.
3. Kane J. Progress defined - Short-term efficacy, long-term effectiveness. Int Clin Psychopharmacol 2001;16(Suppl 1): S1-8.
4. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: A critical overview. Can Med Ass J 2005;172: 1703-11.
5. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New Engl J Med 2002;346: 16-22.
6. Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 2002;16:473-84.
7. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: A systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160:1209-22.
8. Awad AG, Voruganti LN. New antipsychotics, compliance, quality of life, and subjective tolerability-Are patients better off? Can J Psychiatry 2004;49:297-302.
9. Lambert M, Naber D. Current issues in schizophrenia: Overview of patient acceptability, functioning capacity and quality of life. CNS Drugs 2004;18(Suppl 2):5-17; discussion 41-3.
10. Marder SR. Overview of partial compliance. J Clin Psychiatry 2003;64(Suppl 16):3-9.
11. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: Is there a difference between typical and atypical agents? Am J Psychiatry 2002;159:103-8.
12. Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: Our patients can do better. J Clin Psychiatry 2003;64:1308-15.
13. Bhanji NH, Chouinard G, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol 2004;14:87-92.
14. Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, et al. Adherence to treatment with antipsychotic medication and health care costs among medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692-9.
15. Mahmoud R, Engelhart LM, Janagap C, Oster G, Ollendorf D. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder - Symptoms, quality of life and resource use under customary clinical care. Clin Drug Invest 2004;24:275-86.
16. Barnes TR, Curson DA. Long-term depot antipsychotics. A risk-benefit assessment. Drug Saf 1994;10:464-79.
17. Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 2003; 64(Suppl 16):18-23.
18. Pereira S, Pinto R. A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiatr Scand 1997;95:464-8.
19. Babiker IE. Comparative efficacy of long-acting depot and oral neuroleptic medications in preventing schizophrenic recidivism. J Clin Psychiatry 1987;48:94-7.
20. Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L. Depot antipsychotic drugs. Place in therapy. Drugs 1994;47: 741-73.
21. Walburn J, Gray R, Gournay K, Quraishi S, David AS. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001;179:300-7.
22. Hay J. Complications at site of injection of depot neuroleptics. Br Med J 1995;311:421.
23. Bloch Y, Mendlovic S, Strupinsky S, Altshuler A, Fennig S, Ratzoni G. Injections of depot antipsychotic medications in patients suffering from schizophrenia: Do they hurt? J Clin Psychiatry 2001;62:855-9.
24. Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: A randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004;161:985-95.
25. Chue P. Risperidone long-acting injection. Expert Rev. Neurotherapeutics 2003;3:435-46.
26. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-32.
27. Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca P, Chrzanowski W, et al. Treatment of schizophrenia with long-acting injectable risperidone: A 12-month openlabel trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003;64:1250-7.
28. Eriksson L, Almqvist A, Mehnert A, Ingham MP, Eriksson B. Treatment with long acting risperidone significantly reduces the need for institutional psychiatric care regardless of previous treatment. In: 45th Annual and 4th Mediterranean Meeting of the Scandinavian College of Neuro-Psychopharmacology (SCNP); 21-24 April 2004 Juan-les-Pins, France. Nord J Psychiatry 2004;58:94-5.
29. Turner M, Urquhart E. Long term benefits of treatment with risperidone long-acting injection in patients with schizophrenia. Int J Neuropsychopharmacol 2004;7(Suppl 1):S399.
30. Moeller H, Llorca P, Sacchetti E, Martin S, Medori R, Parellada E. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 2005;20:121-30.
31. Nasrallah HA, Duchesne I, Mehnert A, Janagap C, Eerdekens M. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J Clin Psychiatry 2004;65:531-6.
32. Lasser RA, Bossie CA, Gharabawi GM, Kane JM. Remission in schizophrenia: Results from a 1-year study of longacting risperidone injection. Schizophr Res 2005;77:215-27.
33. Os JV, Bossie CA, Lasser RA. Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. Int Clin Psychopharmacol 2004;19:229-32.
34. Lasser RA, Bossie CA, Gharabawi GM, Turner M. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry 2004;19:219-25.
35. Llorca PM, Bouhours P, Moreau-Mallet V. Improved symptom control, functioning and satisfaction in French patients treated with risperidone long-acting injectable. European Psychiatry 2005.
36. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
37. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
38. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials. J Clin Psychiatry 1997;58:538-46.
39. Guy W. Clinical global impressions. In: ECDEU Assessment Manual for Psychopharmacology. rev. ed. Revised DHEW Pub. No. (ADM). Rockville: Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976. p 218-20.
40. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
41. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-63.
42. Chouinard G, Ross-Chouinard A, Annable L. The extrapyramidal symptom rating scale. Can J Neurol Sci 1980;7: 233.
43. Turner M, Eerdekens E, Jacko M, Eerdekens M. Long-acting injectable risperidone: Safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol 2004;19:241-9.
44. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
45. Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004;65(Suppl 7):4-18; quiz 19-20.
46. Chue P, Cheung R. The impact of weight gain associated with atypical antipsycotic use in schizophrenia. Acta Neuropsychiatr 2004;16:1-11.